|
|
|
|
|
Ibrahim Alghamdi, Christos Anagnostopoulos and Dimitrios P. Pezaros
In recent years, there has been a significant increase in the use of mobile devices and their applications. Meanwhile, cloud computing has been considered as the latest generation of computing infrastructure. There has also been a transformation in cloud...
ver más
|
|
|
|
|
|
|
|
|
|
|
Dhiaa Musleh, Ali Alkhwaja, Ibrahim Alkhwaja, Mohammed Alghamdi, Hussam Abahussain, Mohammed Albugami, Faisal Alfawaz, Said El-Ashker and Mohammed Al-Hariri
Obesity is increasingly becoming a prevalent health concern among adolescents, leading to significant risks like cardiometabolic diseases (CMDs). The early discovery and diagnosis of CMD is essential for better outcomes. This study aims to build a reliab...
ver más
|
|
|
|
|
|
|
|
|
|
|
Dhiaa A. Musleh, Ibrahim Alkhwaja, Ali Alkhwaja, Mohammed Alghamdi, Hussam Abahussain, Faisal Alfawaz, Nasro Min-Allah and Mamoun Masoud Abdulqader
YouTube is a popular video-sharing platform that offers a diverse range of content. Assessing the quality of a video without watching it poses a significant challenge, especially considering the recent removal of the dislike count feature on YouTube. Alt...
ver más
|
|
|
|
|
|
|
|
|
|
|
Haya I. Aljohar, Abdulmajeed A. Alghamdi, Nasr Y. Khalil, Hany W. Darwish, Rashad Al-Salahi and Ibrahim A. Darwish
The Food and Drug Administration (FDA) has approved duvelisib (DUV) for managing follicular lymphoma, small lymphocytic lymphoma, and relapsed or refractory chronic lymphocytic leukemia. Seliciclib (SEL) is a candidate drug for these cancers, neurodegene...
ver más
|
|
|
|
|
|